The value of amphotericin B in the treatment of invasive fungal infections

Journal of Critical Care

Volumn 26, Issue 2, 2011, Pages 225.e1-225.e10

  Klepser, Michael ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

Antifungal drugs; Azoles; Echinocandins; Polyenes; Resistance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POLYENE; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; VORICONAZOLE;

ANOREXIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; FEVER; HEADACHE; HEMOLYSIS; HUMAN; HYPOTENSION; INFECTION RISK; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG ASPERGILLOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHLEBITIS; PHOTOTOXICITY; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC MYCOSIS; TACHYPNEA; TREATMENT PLANNING; VISUAL DISORDER; VOMITING; ZYGOMYCOSIS;

EID: 79953786429     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.08.005     Document Type: Article

References (115)

1. Pfaller M.A., Pappas P.G., Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006, 43(Suppl 1):S3-S14.
2. Pappas P.G., Rex J.H., Lee J., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
3. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
4. Hajjeh R.A., Sofair A.N., Harrison L.H., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
5. Marr K.A., Seidel K., White T.C., et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316.
6. Price M.F., LaRocco M.T., Gentry L.O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994, 38:1422-1424.
7. Trick W.E., Fridkin S.K., Edwards J.R., et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
8. Baddley J.W., Stroud T.P., Salzman D., et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32:1319-1324.
9. Denning D.W., Marinus A., Cohen J., et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998, 37:173-180.
10. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
11. Torres H.A., Rivero G.A., Lewis R.E., et al. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003, 46:25-28.
12. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
13. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503-509.
14. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
15. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
16. Morgan J., Meltzer M.I., Plikaytis B.D., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547.
17. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
18. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33:1824-1833.
19. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000, 79:250-260.
20. Tong K.B., Lau C.J., Murtagh K., Layton A.J., et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009, 13:24-36.
21. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
22. Andriole V.T. The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999, 44:151-162.
23. Diekema D.J., Messer S.A., Hollis R.J., et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003, 41:3623-3626.
24. Dodds Ashley E., Lewis R., Lewis J., et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S28-39.
25. Oakley K.L., Moore C.B., Denning D.W. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999, 43:1264-1266.
26. Pfaller M.A., Messer S.A., Hollis R.J., et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032-1037.
27. Verweij P.E., Mellado E., Melchers W.J.G. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356:1481-1483.
28. Alastruey-Izquierdo A., Cuenca-Estrella M., Monzon A., et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008, 61:805-809.
29. Meletiadis J., Meis J.F.G.M., Mouton J.W., et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002, 46:62-68.
30. Dilflucan [package insert] 2004, Pfizer Inc., New York, NY.
31. Noxafil [package insert] 2008, Schering Corporation, Kenilworth, NJ.
32. Sporanox [package insert] 2006, Janssen Pharmaceutica Products, LP, Titusville, NJ.
33. Vfend [package insert] 2006, Pfizer Inc., New York, NY.
34. Andes D., Pascual A., Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53:24-34.
35. Krishna G., Martinho M., Chandrasekar P., et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007, 27:1627-1636.
36. Purkins L., Wood N., Ghahramani P., et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46:2546-2553.
37. Foulds G., Brennan D.R., Wajszczuk C., et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988, 28:363-366.
38. Lutsar I., Roffey S., Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003, 37:728-732.
39. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001, 45:1854-1859.
40. Nakai T., Uno J., Ikeda F., Tawara S., et al. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003, 47:1376-1381.
41. Cancidas [package insert] 2005, Merck and Co. Inc., Whitehouse Station, NJ.
42. Eraxis [package insert] 2006, Pfizer Inc., New York, NY.
43. Mycamine [package insert] 2005, Astellas Pharma US Inc., Deerfield IL.
44. Boucher H.W., Groll A.H., Chiou C.C., et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004, 64:1997-2020.
45. Denning D.W. Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151.
46. Gauthier G.M., Nork T.M., Prince R., et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005, 41:e27-8.
47. Suzuki T., Uno T., Chen G., et al. Ocular distribution of intravenously administered micafungin in rabbits. J Infect Chemother 2008, 14:204-207.
48. Zaas A.K. Echinocandins: a wealth of choice-how clinically different are they?. Curr Opin Infect Dis 2008, 21:426-432.
49. Georgopapadakou N.H., Walsh T.J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996, 40:279-291.
50. Diamond D.M., Bauer M., Daniel B.E., et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998, 42:528-533.
51. Ghannoum M.A., Ibrahim A.S., Fu Y., et al. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992, 30:2881-2886.
52. Galan-Sanchez F., Garcia-Martos P., Rodriguez-Ramos C., et al. Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples. Mycopathologia 1999, 145:109-112.
53. Pavie J., Lacroix C., Hermoso D.G., et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005, 43:4902-4904.
54. Zaas A.K., Boyce M., Schell W., et al. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003, 41:5233-5235.
55. Anaissie E.J., Hachem R., Karyotakis N.C., et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994, 38:2541-2544.
56. Walsh T.J., Melcher G.P., Rinaldi M.G., et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990, 28:1616-1622.
57. Amphocin [package insert] 2003, Pharmacia & Upjohn Co., Kalamazoo, MI.
58. Malani P.N., Depestel D.D., Riddell J., et al. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 2005, 25:690-697.
59. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002, 49(Suppl 1):37-41.
60. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27:296-302.
61. Andes D., Safdar N., Marchillo K., Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006, 50:674-684.
62. Lewis R.E., Liao G., Hou J., et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007, 51:1253-1258.
63. Lewis R.E., Albert N.D., Hou J., et al. Comparative pharmacodynamics of amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-AMB) in a murine model of acute invasive pulmonary zygomycosis 2008.
64. Olson J.A., Adler-Moore J.P., Schwartz J., et al. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006, 50:2122-2131.
65. Groll A.H., Giri N., Petraitis V., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274-282.
66. Clemons K.V., Stevens D.A. Comparative efficacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis. Antimicrob Agents Chemother 2004, 48:1047-1050.
67. Clemons K.V., Stevens D.A. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998, 42:899-902.
68. Ibrahim A.S., Gebremariam T., Husseiny M.I., et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008, 52:1573-1576.
69. Clemons K.V., Espiritu M., Parmar R., et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49:4867-4875.
70. Masia Canuto M., Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002, 2:550-563.
71. Cannon R.D., Lamping E., Holmes A.R., et al. Candida albicans drug resistance another way to cope with stress. Microbiology 2007, 153:3211-3217.
72. Alexander B.D., Schell W.A., Miller J.L., et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005, 80:868-871.
73. Moudgal V., Little T., Boikov D., et al. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005, 49:767-769.
74. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154.
75. Pfaller M.A., Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419-4431.
76. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
77. Orozco A.S., Higginbotham L.M., Hitchcock C.A., et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998, 42:2645-2649.
78. Hakki M., Staab J.F., Marr K.A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006, 50:2522-2524.
79. Hernandez S., Lopez-Ribot J.L., Najvar L.K., et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004, 48:1382-1383.
80. Kahn J.N., Garcia-Effron G., Hsu M., et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007, 51:1876-1878.
81. Krogh-Madsen M., Arendrup M.C., Heslet L., et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006, 42:938-944.
82. Laverdiere M., Lalonde R.G., Baril J., et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006, 57:705-708.
83. Park S., Kelly R., Kahn J.N., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005, 49:3264-3273.
84. Clancy C.J., Nguyen M.H. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999, 43:1289-1290.
85. Dick J.D., Merz W.G., Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980, 18:158-163.
86. Panackal A.A., Imhof A., Hanley E.W., et al. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006, 12:403-408.
87. Safe L.M., Safe S.H., Subden R.E., et al. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol 1977, 23:398-401.
88. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
89. Girmenia C., Moleti M.L., Micozzi A., et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005, 43:5395-5396.
90. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
91. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
92. Ritz N., Ammann R.A., Aebischer C.C., et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr 2005, 164:231-235.
93. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
94. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425-429.
95. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
96. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
97. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
98. Vigouroux S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35-e37.
99. Marr K.A. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008, 21:409-414.
100. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007, 78:275-282.
101. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
102. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
103. Parkins M.D., Sabuda D.M., Elsayed S., et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60:613-618.
104. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.
105. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007, 44:402-409.
106. Lin M.T., Lu H.C., Chen W.L. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001, 33:1621-1627.
107. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250.
108. Cordonnier C., Pautas C., Maury S., et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009, 48:1042-1051.
109. Chapman S.W., Bradsher R.W.J., Campbell G.D.J., et al. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:679-683.
110. Walsh T.J., Groll A., Hiemenz J., et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004, 10(Suppl 1):48-66.
111. Stanzani M., Tumietto F., Vianelli N., et al. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther Clin Risk Manag 2007, 3:1165-1173.
112. Greenberg R.N., Mullane K., van Burik J.H., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
113. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial). Clin Infect Dis 2007, 44:1289-1297.
114. Eriksson U., Seifert B., Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. Br Med J 2001, 322:3221-3226.
115. Peleg A.Y., Woods M.L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004, 54:803-808.